4. Management Outline Stage Stage I & II A Stage IIB, III & IV Radiotherapy alone Chemotherapy alone Combined Modality CCT + Consolidation Radiotherapy
5. Evolution of CCT Single agents MOPP (USA) COPP (UK) MOPP variants ABVD ABVD MOPP Alternating ABVD MOPP Hybrids More intense therapy ?? 1 st Generation 2 nd Generation 3 rd Generation 4 th Generation
13. Dose and Administration 3-4 weekly IV 75 mg/m 2 Cisplatin Daily x 5, Variable IV 50-120 mg/m 2 Etoposide Daily x 5, Variable IV 200 mg/m 2 DTIC Variable IV 5 mg/m 2 Bleomycin 3-4 weekly IV 30-60 mg/m 2 Doxorubicin Weekly IV 0.2 mg/kg/wk Vinblastine Daily PO 0.2 mg/kg/d Chlorambucil Daily PO 2 mg/kg/d Cyclophosphamide Daily PO 50-150 mg/kg/d Procarbazine Weekly IV 0.2 mg/kg Vincristine 4-6 weeks IV 0.2-0.4 mg/kg Nitrogen Mustard Frequency Route Dose Agent
14. Mechanisms of Action Class Alkylating Agents Vinca Alkaloids Anthracyclines Non classic Alkylating agents Podphyllotoxins Bleomycin Cisplatin DNA alkylation & DNA cross linking Disruption of Microtubules with Mitotic arrest Topoisomerase II dependant DNA cleavage Single strand DNA breaks & premitotic G2 block ; 0 6 -Methylguanine mediated cellular cytotoxicity. Topoisomerase II inhibitors DNA adducts and crosslinks Direct DNA damage
15. Toxicity Neurotoxicity, Ototoxicity, Nephrotoxicity Cisplatin BMT (leucopenia & neutropenia), Leukemia Etoposide BMT, Flu like syndrome , Hepatic vein thrombosis DTIC Fever, Skin toxicity, Pulmonary toxicity Bleomycin BMT, Alopecia, N&V, Diarrhea, Cardiac, RT recall Doxorubicin BMT (Neutropenia), Mucositis, Hypertension Vinblastine BMT (Neutropenia, Anemia), N&V, Leukemia Chlorambucil BMT (Thrombocytopenia), SIADH, N&V, Bladder toxicity Cyclophosphamide BMT, N&V, Leukemogenic, Infertility, Psychotic reactions, hypertensive crisis with MAO inhibitor Procarbazine Neurotoxicity, constipation & ANS disturbance Vincristine BMT, N&V, Leukemogenic Nitrogen Mustard Dose Limiting Toxicity Agent
36. ABVD alone : Toxicity S 11.3 5.0 Hematological (Gr III or more) NS 2.9 3.3 Pulmonary (Gr II or more) NS 9.3 8.3 Cardiac (Gr II or more) After Treatment S 1.7 0 Hypotension (Gr III or more) S 5.7 1.7 Fatigue (Gr III or more) S 3.2 0.2 Anorexia (Gr III or more) S 74.6 63.6 Hematological (Gr III or more) NS 7.5 6.6 Cardiac (Gr II or more NS 30.6 24.5 Pulmonary (Gr II or more) In Treatment P MOPP ABV (%) ABVD (%) Toxicity
66. Treatment of recurrence Type Post RT Post CCT CCT alone with ABVD RT Salvage CCT High Dose CCT with stem cell support Late Relapse Early Relapse Primary Progressive HL